CPT code 86832: HLA antibody panel, class I, high-definition qualitative2026 Medicare lab fee · Clinical Laboratory Fee Schedule
A high-definition qualitative test identifies HLA class I antibody specificities, commonly supporting transplant evaluation and monitoring for donor-directed antibodies.
Medicare pays $323.75 for 86832 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$323.75
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2020
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 8 sections
What 86832 covers
This laboratory test detects antibodies against human leukocyte antigen (HLA) class I and identifies their specificities using a high-definition qualitative panel. Solid-phase methods may include bead-based assays, ELISA, or flow cytometry; high-definition testing can distinguish individual antigen specificities. Histocompatibility laboratories perform the analysis on patient serum for transplant evaluation or monitoring, including assessment of HLA sensitization and potential donor-specific antibodies.
Report 86832 for the class I high-definition qualitative antibody panel, rather than for HLA typing or a semiquantitative result. Medicare pays the test through the CLFS only. The 2026 national CLFS amount is $323.75, unchanged since 2020; one amount applies across states and localities, with no geographic or office-versus-facility adjustment.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 86832
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 86832. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Excluded from the physician fee schedule
The physician fee schedule lists 86832 with status X (excluded by statute), so the test itself is paid only from the CLFS.
86832 on the lab fee schedule since 2020
86832 · CLFS 2026 Q4 (current)
$323.75
Unchanged since Jan 1, 2020
27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.
86832 compared with similar tests
- 86833HLA antibodyHigh-definition qualitative$325.80
- Choose 86832 for high-definition qualitative HLA class I antibody identification; choose 86833 for class II.
- 86834HLA antibody panelClass I, semiquantitative$357.56
- Both address HLA class I antibodies, but 86832 is high-definition qualitative testing and 86834 is semiquantitative.
- 86828HLA antibodiesBoth HLA classes$64.19
- 86832 is specific to high-definition qualitative class I antibody identification; 86828 covers qualitative antibody assessment for both HLA classes.
- 86807Transplant antibody screenStandard cytotoxicity method$78.65
- 86807 is cytotoxic antibody screening, whereas 86832 uses a high-definition qualitative panel to identify HLA class I antibody specificities.
86832 billing questions
What does 86832 identify?
It identifies antibody specificities directed against HLA class I using a high-definition qualitative panel. It tests for antibodies, not the patient's HLA type.
When is 86832 used in transplant care?
It may be ordered during transplant evaluation or follow-up to assess HLA class I sensitization and potential donor-specific antibodies.
How does 86832 differ from 86833?
86832 identifies HLA class I antibody specificities; 86833 is the corresponding high-definition qualitative test for HLA class II.
How does 86832 differ from 86834?
86832 reports a high-definition qualitative class I panel. 86834 is the class I semiquantitative panel.
Does Medicare use a local rate for 86832?
No. The CLFS amount is national and applies across localities, without an office-versus-facility adjustment.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 86832 and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist